LIVE: An FDA expert panel is meeting today to discuss Moderna's coronavirus vaccine, likely paving the way for the 2nd authorized COVID-19 shot in the US

<p><img src="https://static1.businessinsider.com/image/5fb6b9bb32f2170011f701a9-2400/moderna covid vaccine record time 2x1.png" border="0" alt="moderna covid vaccine record time 2x1" data-mce-source="Moderna; Samantha Lee/Business Insider"></p><p></p><bi-shortcode id="summary-shortcode" data-type="summary-shortcode" class="mceNonEditable" contenteditable="false">Summary List Placement</bi-shortcode><h3>9:00 AM: Panel kicks off, releasing key voting question</h3><img src="https://static5.businessinsider.com/image/5fdb5f14c910a400192e8052-400-300/900-am-panel-kicks-off-releasing-key-voting-question.jpg" alt="" /><p><p>We are off and running for a marathon meeting expected to wrap up at 5:15 p.m.&nbsp;</p><p>On Tuesday, the FDA released the most detailed results yet from Moderna's late-stage study in preparation for this meeting. The agency's summary showed the two-dose vaccine to be <a href="https://www.businessinsider.com/chart-how-well-moderna-vaccine-prevents-covid-19-infections-2020-12">overwhelmingly protective</a> at preventing symptomatic COVID-19 <a href="https://www.businessinsider.com/safety-and-side-effects-for-modernas-coronavirus-vaccine-2020-12">with no major safety concerns</a>.</p><p>All in all, it's a very similar profile to Pfizer's vaccine, which was authorized last Friday, and <a href="https://www.businessinsider.com/pfizer-moderna-covid-19-vaccines-comparison-how-the-shots-compare-2020-12">we compared what we know about each shot here</a>.</p><p>It's poised to be a long but important day. The panel's recommendation on whether or not to OK Moderna's vaccine is seen as the last remaining barrier to an FDA authorization decision.</p><p>Here's the agenda for the day:&nbsp;</p><p>9:00 a.m. &mdash; Introductions</p><p>9:30 a.m. &mdash; FDA deputy director Doran Fink outlines emergency use authorization</p><p>10:05 a.m. &mdash; Stanford researcher Steven Goodman discusses the possible options for ongoing placebo-controlled vaccine trials, given COVID-19 shots are now being rolled out</p><p>10:45 a.m. &mdash; Moderna chief medical officer Tal Zaks and senior vice president Jacqueline Miller present the biotech's vaccine data</p><p>12:00 p.m. &mdash; Public comment</p><p>1:00 p.m. &mdash; Zaks and Miller answer questions from committee members</p><p>2:00 p.m. &mdash; FDA medical officer Rachel Zhang presents the agency's perspective on the vaccine data</p><p>3:10 p.m. &mdash; Committee discusses, ultimately votes, and adjourns</p></p><br/><br/>
Click here to read full news..